Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Editas Medicine, Inc. (EDIT) AI Forecast

Our AI analyzed Editas Medicine, Inc.. Create a free account to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$EDIT Neutral Signal Full forecast available
Sign Up Free

Editas Medicine, Inc. (EDIT) Stock Forecast 2025

Editas Medicine, Inc. (EDIT) AI Stock Price Forecast & Investment Analysis

Editas Medicine, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Editas Medicine, Inc. (EDIT) - Comprehensive Stock Analysis & Investment Research

Deep dive into Editas Medicine, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on April 18, 2026, 3:05 p.m. (UTC)

Editas Medicine, Inc. Investment Summary

When evaluating whether Editas Medicine, Inc. (EDIT) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Editas Medicine, Inc. (EDIT) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $342 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Editas Medicine, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Editas Medicine, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Editas Medicine, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Editas Medicine, Inc.

Sign Up Free
Corporate Identity

Editas Medicine, Inc. (Stock Symbol: EDIT) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Editas Medicine, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Editas Medicine, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Editas Medicine, Inc....

Unlock Full Company Profile

Get complete details about Editas Medicine, Inc.

Sign Up Free
Revenue & Growth Analysis

Editas Medicine, Inc. generates annual revenues of $40 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Editas Medicine, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Editas Medicine, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Editas Medicine, Inc....

Unlock Financial Analysis

Get complete financial metrics for Editas Medicine, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Editas Medicine, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Editas Medicine, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Editas Medicine, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-166 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Asset Utilization Efficiency

Asset turnover ratio of 0.22x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.

Financial Strength & Leverage

Current ratio of 3.54 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Editas Medicine, Inc. (EDIT) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Editas Medicine, Inc. stock analysis.

Deep dive into Editas Medicine, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Editas Medicine, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Editas Medicine, Inc.:

P/B Ratio 12.52x
Market Cap $342M
Book Value/Share $0.28
Revenue/Share $0.41
FCF/Share $-1.69
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Editas Medicine, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Editas Medicine, Inc.: An ROE of -260.1% indicates room for improvement in shareholder value creation.

ROE -260.1%
ROA -38.1%
ROIC -50.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Editas Medicine, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Editas Medicine, Inc.: A current ratio of 3.54 indicates strong liquidity.

Current Ratio 3.54x
D/E Ratio 5.84x
Financial Leverage 6.84x
Interest Coverage 16.7x
Working Capital $118M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Editas Medicine, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Editas Medicine, Inc.: Free cash flow of $-166M indicates cash challenges that need attention.

Operating Cash Flow -$39M
Free Cash Flow -$166M
Capital Spending -$127M
FCF/Sales -409.3%
CapEx/Sales 314.2%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Editas Medicine, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Editas Medicine, Inc.: An asset turnover of 0.22x suggests room for improvement in asset utilization.

Asset Turnover 0.22x
Receivables Turnover 2.7x
Fixed Assets Turnover 11.4x
Days Sales Outstanding 137 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Editas Medicine, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Editas Medicine, Inc.: With annual revenue of $40M, Editas Medicine, Inc. represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $40M
Operating Income -$71M
Net Income -$70M
R&D Expense $36M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 164%
Cash & Short-term Investments 147%
Total Liabilities 159%
Short-term Debt 44%
Accounts Receivable 15%
Dividend & Shareholder Information
Shares Outstanding 98M

Latest Editas Medicine, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Editas Medicine, Inc. (EDIT) stock price and investment outlook.

More news available

Sign up free to read all 11 news articles and stay updated on market developments.

Sign Up Free to Read More

Editas Medicine, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Editas Medicine, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Acumen Pharmaceuticals, Inc. ABOS ██% $204M x 2.9x
Abpro Holdings, Inc. ABP ██% $310K x 0.0x
Abpro Holdings, Inc. ABPO ██% $880K x x
Arcellx, Inc. ACLX ██% $6.66B x 16.6x
Alpha Cognition Inc. ACOG ██% $151M x 2.4x
Adaptimmune Therapeutics Plc ADAP ██% $77M -13.2x -11.8x
Adma Biologics, Inc. ADMA ██% $2.62B 17.8x 5.5x
Adaptive Biotechnologies Corp ADPT ██% $2.23B x 10.2x
Adverum Biotechnologies, Inc. ADVM ██% $95M -1.8x 2.2x
Agenus Inc AGEN ██% $169M 1471.2x x
Agentix Corp. AGTX ██% $2M x x
Aim Immunotech Inc. AIM ██% $4M x x
Aim Immunotech Inc. AIMI ██% $1M x x
Alector, Inc. ALEC ██% $284M x 9.3x
Aligos Therapeutics, Inc. ALGS ██% $41M x 0.8x
Allogene Therapeutics, Inc. ALLO ██% $792M x 2.7x
Alvotech ALVO ██% $1.13B x x
Amgen Inc AMGN ██% $191.44B 24.8x 22.1x
Apogee Therapeutics, Inc. APGE ██% $6.31B x x
Aptose Biosciences Inc. APTOF ██% $4M x x
Argenx Se ARGX ██% $52.54B x x
Armata Pharmaceuticals, Inc. ARMP ██% $421M x x
Artiva Biotherapeutics, Inc. ARTV ██% $307M x 2.8x
Leonabio, Inc. ATHA ██% $23M -0.2x 0.9x
Atara Biotherapeutics, Inc. ATRA ██% $43M 1.3x x
Atyr Pharma Inc ATYR ██% $84M x 1.2x
Aura Biosciences, Inc. AURA ██% $464M x 3.4x
Autolus Therapeutics Plc AUTL ██% $426M x 2.4x
Anavex Life Sciences Corp. AVXL ██% $337M x 2.7x
Bioatla, Inc. BCAB ██% $8M x x
Biocardia, Inc. BCDA ██% $13M x 14.2x
Brainstorm Cell Therapeutics Inc. BCLI ██% $10M x x
Biocryst Pharmaceuticals Inc BCRX ██% $2.38B 9.0x x
Black Diamond Therapeutics, Inc. BDTX ██% $175M 7.8x 1.6x
Beam Therapeutics Inc. BEAM ██% $3.19B x 2.6x
Biogen Inc. BIIB ██% $26.03B 20.1x 1.4x
Biontech Se BNTX ██% $26.03B x x
Cabaletta Bio, Inc. CABA ██% $346M x 3.1x
Candel Therapeutics, Inc. CADL ██% $467M x 9.0x
C4 Therapeutics, Inc. CCCC ██% $283M x 1.1x
Cidara Therapeutics, Inc. CDTX ██% $6.49B -1.0x 15.4x
Creative Medical Technology Holdings, Inc. CELZ ██% $9M x 1.2x
Cero Therapeutics Holdings, Inc. CERO ██% $1M x x
Cullinan Therapeutics, Inc. CGEM ██% $907M x 2.2x
Compugen Ltd CGEN ██% $267M 3.8x 2.6x
Cg Oncology, Inc. CGON ██% $5.92B x 7.9x
Cognition Therapeutics Inc CGTX ██% $106M x 3.1x
Coherus Oncology, Inc. CHRS ██% $297M 1.8x 4.9x
Calidi Biotherapeutics, Inc. CLDI ██% $3M x 0.8x
Cellectis S.A. CLLS ██% $456M x x
Compass Therapeutics, Inc. CMPX ██% $1.07B x 5.4x
Mosaic Immunoengineering Inc. CPMV ██% $5M x x
Caribou Biosciences, Inc. CRBU ██% $142M -1.5x 1.0x
Cardiff Oncology, Inc. CRDF ██% $123M x 2.7x
Cardiol Therapeutics Inc. CRDL ██% $169M x x
Curis Inc CRIS ██% $24M x 4.4x
Crispr Therapeutics Ag CRSP ██% $5.56B x 2.9x
Champions Oncology, Inc. CSBR ██% $84M x 19.6x
Cel Sci Corp CVM ██% $42M x 3.7x
Dbv Technologies S.A. DBVT ██% $1.26B x 7.5x
Dbv Technologies S.A. DBVTF ██% $10K x 0.0x
Ginkgo Bioworks Holdings, Inc. DNA ██% $467M x 0.9x
Denali Therapeutics Inc. DNLI ██% $3.21B x 3.2x
Precision Biosciences Inc DTIL ██% $190M x 2.1x
Dyadic International Inc DYAI ██% $32M x 25.7x
Editas Medicine, Inc. EDIT ██% $342M x 12.5x
Eloxx Pharmaceuticals, Inc. ELOX ██% $560K x x
Elutia Inc. ELUT ██% $48M 0.9x 1.7x
Engene Therapeutics Inc. ENGN ██% $541M x 1.9x
Entera Bio Ltd. ENTX ██% $70M x 5.3x
Viskase Holdings, Inc. ENZN ██% $4M x x
Estrella Immunopharma, Inc. ESLA ██% $80M x x
Evaxion A/S EVAX ██% $37M x x
Exelixis, Inc. EXEL ██% $11.78B 15.1x 5.5x
Exozymes Inc. EXOZ ██% $89M x 26.2x
Fate Therapeutics Inc FATE ██% $160M x 0.8x
4d Molecular Therapeutics, Inc. FDMT ██% $536M x 1.1x
Fennec Pharmaceuticals Inc. FENC ██% $232M x 6.5x
Finch Therapeutics Group, Inc. FNCH ██% $12M 0.5x 0.9x
Finch Therapeutics Group, Inc. FNCHQ ██% $12M 0.5x 0.9x
Futuretech Ii Acquisition Corp. FTII ██% $52M x x
Futuretech Ii Acquisition Corp. FTIIU ██% $14M x -0.8x
Gilead Sciences, Inc. GILD ██% $170.81B 20.1x 7.5x
Monte Rosa Therapeutics, Inc. GLUE ██% $1.58B x 6.8x
Genenta Science S.P.A. GNTA ██% $17M x 1.4x
Green Planet Bio Engineering Co. Ltd. GPLB ██% $340K x x
Greenland Mines Ltd GRML ██% $51M x 5.1x
Halozyme Therapeutics, Inc. HALO ██% $8.16B 25.8x 167.2x
Humacyte, Inc. HUMA ██% $158M x 50.7x
Immunitybio, Inc. IBRX ██% $7.79B x x
Inhibikase Therapeutics, Inc. IKT ██% $242M x 1.4x
Imagenebio, Inc. IMA ██% $66M x 0.5x
Immunocore Holdings Plc IMCR ██% $1.59B x 4.2x
Immatics N.V. IMTX ██% $1.50B x x
Immunovant, Inc. IMVT ██% $5.96B x 6.0x
In8bio, Inc. INAB ██% $14M x 0.5x
Inhibrx Biosciences, Inc. INBX ██% $873M -6.8x 109.2x
Mink Therapeutics, Inc. INKT ██% $71M x x
Inmune Bio, Inc. INMB ██% $39M x 1.6x
Intensity Therapeutics, Inc. INTS ██% $13M x 1.1x
Iovance Biotherapeutics, Inc. IOVA ██% $1.59B x 2.3x
Century Therapeutics, Inc. IPSC ██% $467M x 2.9x
Invivyd, Inc. IVVD ██% $491M x 2.0x
Jasper Therapeutics, Inc. JSPR ██% $29M x 6.9x
Kalaris Therapeutics, Inc. KLRS ██% $145M x 1.8x
Klotho Neurosciences, Inc. KLTO ██% $56M x 5.7x
Kodiak Sciences Inc. KOD ██% $2.77B x 17.6x
Krystal Biotech, Inc. KRYS ██% $8.00B 39.1x 6.6x
Kymera Therapeutics, Inc. KYMR ██% $7.13B x 4.5x
Kyverna Therapeutics, Inc. KYTX ██% $600M x 2.6x
Ladrx Corp LADX ██% $20K x 0.1x
Lineage Cell Therapeutics, Inc. LCTX ██% $416M x 9.3x
Lenz Therapeutics, Inc. LENZ ██% $319M x 1.1x
Liminatus Pharma, Inc. LIMN ██% $10M x x
Leonabio, Inc. LONA ██% $83M x 3.0x
Lexeo Therapeutics, Inc. LXEO ██% $504M x 2.0x
Maze Therapeutics, Inc. MAZE ██% $1.39B x 3.9x
Mesoblast Ltd MESO ██% $2.15B x x
Meiragtx Holdings Plc MGTX ██% $937M x x
Metagenomi Therapeutics, Inc. MGX ██% $56M x 0.4x
Molecular Partners Ag MOLN ██% $170M x x
Moderna, Inc. MRNA ██% $21.17B x 2.5x
Neurocrine Biosciences Inc NBIX ██% $13.34B 27.9x 4.1x
Nkgen Biotech, Inc. NKGN ██% $2M -0.1x -0.2x
Neumora Therapeutics, Inc. NMRA ██% $375M x 3.6x
Novavax Inc NVAX ██% $1.44B 3.3x x
Ocugen, Inc. OCGN ██% $622M x x
Outlook Therapeutics, Inc. OTLK ██% $32M x x
Palisade Bio, Inc. PALI ██% $402M x 3.1x
Passage Bio, Inc. PASG ██% $37M x 2.0x
Vaxcyte, Inc. PCVX ██% $8.17B x 3.0x
Biomx Inc. PHGE ██% $16M x x
Pluri Inc. PLUR ██% $36M x x
Protalix Biotherapeutics, Inc. PLX ██% $187M x 3.9x
Pharmacyte Biotech, Inc. PMCB ██% $8M x 0.2x
Prime Medicine, Inc. PRME ██% $688M x 5.7x
Prokidney Corp. PROK ██% $657M x x
Pelthos Therapeutics Inc. PTHS ██% $74M x 1.9x
Qiagen N.V. QGEN ██% $8.95B x 2.4x
Quince Therapeutics, Inc. QNCX ██% $22M x 21.1x
Qrons Inc. QRON ██% $150K x x
Replimune Group, Inc. REPL ██% $173M x 0.8x
Repligen Corp RGEN ██% $7.39B 151.2x 3.5x
Regenxbio Inc. RGNX ██% $483M x 4.7x
Relay Therapeutics, Inc. RLAY ██% $2.91B x 5.1x
Revolution Medicines, Inc. RVMD ██% $29.28B x 18.0x
Recursion Pharmaceuticals, Inc. RXRX ██% $2.00B x 1.8x
Sab Biotherapeutics, Inc. SABS ██% $271M 20.4x 1.8x
Sana Biotechnology, Inc. SANA ██% $939M x 5.8x
Scilex Holding Co SCLX ██% $49M x x
Scinai Immunotherapeutics Ltd. SCNI ██% $2M x 0.3x
Sangamo Therapeutics, Inc SGMO ██% $108M x x
Solid Biosciences Inc. SLDB ██% $849M x 4.7x
Silexion Therapeutics Corp SLXN ██% $4M x 1.7x
Senti Biosciences, Inc. SNTI ██% $34M x 6.1x
Scholar Rock Holding Corp SRRK ██% $5.42B x 22.1x
Surrozen, Inc./De SRZN ██% $371M x x
Sutro Biopharma, Inc. STRO ██% $523M x x
Protara Therapeutics, Inc. TARA ██% $292M x 1.5x
Tarsus Pharmaceuticals, Inc. TARS ██% $2.86B x 8.3x
Tc Biopharm (Holdings) Plc TCBPY ██% $10K x 0.0x
Tscan Therapeutics, Inc. TCRX ██% $68M x 0.6x
Bio-Techne Corp TECH ██% $9.23B 113.8x 4.6x
Tectonic Therapeutic, Inc. TECX ██% $553M x 2.2x
Instil Bio, Inc. TIL ██% $60M x 0.5x
Tenaya Therapeutics, Inc. TNYA ██% $170M x 1.4x
Tourmaline Bio, Inc. TRML ██% $1.23B -3.5x 4.8x
Taysha Gene Therapies, Inc. TSHA ██% $1.79B x 7.2x
Titan Pharmaceuticals Inc TTNP ██% $6M -0.5x 2.2x
Tevogen Bio Holdings Inc. TVGN ██% $29M x x
Twist Bioscience Corp TWST ██% $3.73B x 8.2x
Voyager Acquisition Corp./Cayman Islands VACH ██% $416M 46.3x x
Voyager Acquisition Corp./Cayman Islands VACHU ██% $68M 6.7x 0.0x
Valneva Se VALN ██% $543M x x
Vericel Corp VCEL ██% $1.80B 109.2x 5.1x
Vir Biotechnology, Inc. VIR ██% $1.71B x 2.2x
Vivosim Labs, Inc. VIVS ██% $4M x 0.9x
Vor Biopharma Inc. VOR ██% $785M x x
Vaxart, Inc. VXRT ██% $180M 11.0x 2.1x
Voyager Therapeutics, Inc. VYGR ██% $242M x 1.2x
Windtree Therapeutics Inc /De/ WINT ██% $490K x x
X4 Pharmaceuticals, Inc XFOR ██% $385M x 2.1x
Zeo Scientifix, Inc. ZEOX ██% $16M x x
Zivo Bioscience, Inc. ZIVO ██% $8M x x
Zura Bio Ltd ZURA ██% $543M x 5.3x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Editas Medicine, Inc. Stock Forecast

How accurate are Editas Medicine, Inc. stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for EDIT predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Editas Medicine, Inc. stock price forecasts?

Our analysis considers Editas Medicine, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Editas Medicine, Inc. a good investment in 2025?

Based on our AI analysis, Editas Medicine, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Editas Medicine, Inc. forecasts updated?

Editas Medicine, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Editas Medicine, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...